Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Monoclonal Antibody for Patients with Covid-19. Reply

    Research output: Contribution to journalLetterpeer-review

  4. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Effect of Dapagliflozin on Clinical Outcomes in Patients with Chronic Kidney Disease, With and Without Cardiovascular Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  • George L Bakris
  • Rajiv Agarwal
  • Stefan D Anker
  • Bertram Pitt
  • Luis M Ruilope
  • Peter Rossing
  • Peter Kolkhof
  • Christina Nowack
  • Patrick Schloemer
  • Amer Joseph
  • Gerasimos Filippatos
  • FIDELIO-DKD Investigators
View graph of relations

BACKGROUND: Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes. However, its long-term effects on kidney and cardiovascular outcomes are unknown.

METHODS: In this double-blind trial, we randomly assigned 5734 patients with CKD and type 2 diabetes in a 1:1 ratio to receive finerenone or placebo. Eligible patients had a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of 30 to less than 300, an estimated glomerular filtration rate (eGFR) of 25 to less than 60 ml per minute per 1.73 m2 of body-surface area, and diabetic retinopathy, or they had a urinary albumin-to-creatinine ratio of 300 to 5000 and an eGFR of 25 to less than 75 ml per minute per 1.73 m2. All the patients were treated with renin-angiotensin system blockade that had been adjusted before randomization to the maximum dose on the manufacturer's label that did not cause unacceptable side effects. The primary composite outcome, assessed in a time-to-event analysis, was kidney failure, a sustained decrease of at least 40% in the eGFR from baseline, or death from renal causes. The key secondary composite outcome, also assessed in a time-to-event analysis, was death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure.

RESULTS: During a median follow-up of 2.6 years, a primary outcome event occurred in 504 of 2833 patients (17.8%) in the finerenone group and 600 of 2841 patients (21.1%) in the placebo group (hazard ratio, 0.82; 95% confidence interval [CI], 0.73 to 0.93; P = 0.001). A key secondary outcome event occurred in 367 patients (13.0%) and 420 patients (14.8%) in the respective groups (hazard ratio, 0.86; 95% CI, 0.75 to 0.99; P = 0.03). Overall, the frequency of adverse events was similar in the two groups. The incidence of hyperkalemia-related discontinuation of the trial regimen was higher with finerenone than with placebo (2.3% and 0.9%, respectively).

CONCLUSIONS: In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo. (Funded by Bayer; FIDELIO-DKD ClinicalTrials.gov number, NCT02540993.).

Original languageEnglish
JournalThe New England journal of medicine
Volume383
Issue number23
Pages (from-to)2219-2229
Number of pages11
ISSN0028-4793
DOIs
Publication statusPublished - 3 Dec 2020

ID: 61375637